# Encellin

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/encellin

- Industry: Medical Devices & Equipment
- Headquarters: San Francisco, US
- Website: www.encellin.com
- Total disclosed funding: $16M
- Latest round: Series A (Dec 13, 2023)
- Investors on record: 4

## About

Based in the US, Encellin develops innovative therapeutic solutions focusing on Encapsulated Cell Replacement Therapy (ENCRT) to treat endocrine disorders such as type 1 diabetes.Encellin, founded in 2016, is headquartered in San Francisco, US, and specializes in advanced cell encapsulation technology. The company has received Series A funding amounting to USD 9.94 mn on December 13, 2023, led by Khosla Ventures. The CEO, Crystal Nyitray, is one of the co-founders, alongside Ronald Martell. Encellin has executed 2 deals to date, with its total raised amount reaching USD 9.94 mn and a current valuation of USD 39.793 mn.Encellin specializes in the development of advanced therapeutic solutions, focusing on its core product, Encapsulated Cell Replacement Therapy (ENCRT). This innovative therapy addresses endocrine disorders by enhancing cell survival, allowing encapsulated cells to function as smart molecular factories that release therapeutics in response to physiological needs. Encellin targets type 1 diabetes, particularly addressing hypoglycemia, a significant clinical need. Its therapies are designed for both clinical and potential direct-to-consumer use, primarily in regions like North America, Europe, and parts of Asia with high prevalence of endocrine disorders.Encellin generates revenue through the commercialization of its ENCRT technology aimed at healthcare institutions that specialize in managing endocrine disorders. The company engages in B2B transactions with healthcare facilities that purchase its therapy for treatment protocols. Partnerships with hospitals and clinics are crucial, enabling direct distribution to patients with conditions like type 1 diabetes. Pricing details for the product remain undisclosed, but the focus is on providing a comprehensive therapeutic solution that supports patient care over time, facilitated by direct sales and contractual agreements with healthcare organizations.In December 2023, Encellin raised USD 9.94 mn in Series A funding, led by Khosla Ventures and supported by Y Combinator, aimed at accelerating its Phase 1 clinical trial for subcutaneous transplantation of primary islets within Encellin's ENCRT for type 1 diabetes. The company plans to expand into new geographic markets, particularly targeting regions with a high prevalence of endocrine disorders, and will utilize recent funding to support these initiatives.

## Funding rounds

- Series A, Dec 13, 2023, $9.9M — Khosla Ventures, Y Combinator
- Seed, Aug 5, 2021, $5.9M — Khosla Ventures, Y Combinator, Sand Hill Angels, Endurance28

## Investors

- Khosla Ventures (https://capitalatlas.ai/funds/khosla-ventures) — Seed, Series A
- Y Combinator (https://capitalatlas.ai/funds/y-combinator) — Seed, Series A
- Sand Hill Angels (https://capitalatlas.ai/funds/sand-hill-angels) — Seed
- Endurance28 (https://capitalatlas.ai/funds/endurance28) — Seed